This review summarizes the evidence for MitraClip as a percutaneous treatment option for selected high-risk patients with mitral regurgitation.
Answers are grounded in this paper and cite their sources.
Supports individualized MitraClip consideration in high-risk mitral regurgitation; leaves open need for prospective trials on selection and durability.
Mitral regurgitation is an increasing valvular disease that represents a difficult management challenge. Surgical treatment for degenerative mitral regurgitation is the standard of care treatment. Percutaneous therapies have emerged rapidly over the past years as an option for treatment of mitral regurgitation for selected, predominantly high-risk patients. Catheter-based devices mimic these surgical approaches with less procedural risk. Mitraclip® implantation mimics the surgical edge-to-edge leaflet repair technique, reducing the regurgitant area. We review the increasing evidence with the Mitraclip device reported to date.
No takes yet. Share an insight, caveat, or question.
Alegría‐Barrero et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: